SGCB and pulmonary arterial hypertension: One such oral sGC agonist, riociguat (Adempas®), was the first drug approved targeting the NO pathway for the treatment of PAH, and activates sGC directly despite the absence of NO (Klinger and Kadowitz, 2017).